The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

During a live event, Barbara T. Ma, MD, MS, reviewed guidelines on management and best practices for the use of tumor-infiltrating lymphocytes in melanoma.

Theresa Medina, MD, discusses the clinical potential of lifileucel, a tumor-infiltrating lymphocyte therapy, for patients with advanced melanoma.

An expert discusses how recent clinical advancements and biomarker-driven strategies are reshaping first-line treatment decisions in metastatic triple-negative breast cancer (mTNBC), emphasizing the ...

An expert discusses how emerging trial data, particularly from ASCENT-04, are reshaping first-line treatment strategies for PD-L1–positive metastatic triple-negative breast cancer (mTNBC) by ...

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

The FDA evaluates glofitamab and daratumumab for lymphoma and myeloma treatments, highlighting trial demographics and ...

Ayal Aizer, MD, MHS, discusses the findings of a phase 3 study investigating the use of stereotactic radiation vs whole-brain radiation in patients with 5 to 20 brain metastases.

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...